Mitochondrial aldehyde dehydrogenase rescues against diabetic cardiomyopathy through GSK3β-mediated preservation of Mitochondrial integrity and parkin-mediated mitophagy.

ALDH2 GSK3β cardiac contraction diabetes mitochondrial function mitophagy

Journal

Journal of molecular cell biology
ISSN: 1759-4685
Titre abrégé: J Mol Cell Biol
Pays: United States
ID NLM: 101503669

Informations de publication

Date de publication:
28 Sep 2023
Historique:
medline: 29 9 2023
pubmed: 29 9 2023
entrez: 29 9 2023
Statut: aheadofprint

Résumé

Mitochondrial aldehyde dehydrogenase (ALDH2) offers proven cardiovascular benefit although its impact in diabetes remains elusive. This study examined the effect of ALDH2 overexpression (OE) and knockout (KO) on diabetic cardiomyopathy and mechanism involved with a focus on mitochondrial integrity. ALDH2 OE and KO mice were challenged with streptozotocin (STZ, 200 mg/kg. i.p.) to establish diabetes. Diabetic patients displayed reduced plasma ALDH2 activity, cardiac remodeling and diastolic dysfunction. STZ challenge prompted reduced respiratory exchange ratio (RER), dampened fractional shortening, ejection fraction, increased LV end systolic and diastolic diameters, cardiac remodeling, cardiomyocyte contractile and intracellular Ca2+ defects (depressed peak shortening and maximal velocity of shortening/relengthening, prolonged relengthening, dampened intracellular Ca2+ rise and clearance), myocardial ultrastructural injury, oxidative stress, apoptosis and mitochondrial damage, the effects of which were overtly attenuated and accentuated by ALDH2 OE and KO, respectively. Immunoblotting revealed downregulated mitochondrial proteins PPARγ coactivator 1α (PGC-1α) and UCP-2, Ca2+ regulatory proteins including SERCA and Na+-Ca2+ exchanger, elevated phospholamban, dampened autophagy and mitophagy (LC3B ratio, TOM20, Parkin, FUNDC1 and BNIP3), disrupted phosphorylation of Akt, GSK3β and Foxo3a, and elevated PTEN phosphorylation, the effect of which was reversed and worsened by ALDH2 OE and KO, respectively (except FUNDC1 and BNIP3). In vivo and in vitro data revealed that novel ALDH2 activator torezolid/Alda-1 protected against STZ or high glucose-induced cardiac anomalies, the effect was nullified by inhibition of Akt, GSK3β, Parkin and mitochondrial coupling. Our data discerned a vital role for ALDH2 in diabetic cardiomyopathy possibly through regulation of Akt, GSK3β activation, parkin mitophagy and mitochondrial function.

Identifiants

pubmed: 37771085
pii: 7285806
doi: 10.1093/jmcb/mjad056
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences.

Auteurs

Yingmei Zhang (Y)

Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital Fudan University, Shanghai, China710032.
National Clinical Research Center for Interventional Medicine, Shanghai 200032, China.

Rongjun Zou (R)

Department of Cardiovascular Surgery, Guangdong Provincial Hospital of Chinese Medicine, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, Guangdong, China.
The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong, China.

Miyesaier Abudureyimu (M)

National Clinical Research Center for Interventional Medicine, Shanghai 200032, China.
Cardiovascular Department, Shanghai Xuhui Central Hospital, Fudan University, Shanghai 200031, China.

Qiong Liu (Q)

Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education, School of Life Sciences and Medicine, Northwest University, Xi'an, China.
Xi'an Key Laboratory of Cardiovascular and Cerebrovascular Diseases, Xi'an No.3 Hospital, The Affiliated Hospital of Northwest University, School of Life Sciences and Medicine, Northwest University, Xi'an, China.

Jipeng Ma (J)

Department of Cardiovascular Surgery, Xijing Hospital, Air Force Medical University 710032 China.

Haixia Xu (H)

Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital Fudan University, Shanghai, China710032.
National Clinical Research Center for Interventional Medicine, Shanghai 200032, China.
Department of Cardiology, Affiliated Hospital of Nantong University, Jiangsu 226001, China.

Wei Yu (W)

School of Pharmacy, Xianning Medical College, Hubei University of Science and Technology, Xianning 437100, China.

Jian Yang (J)

Department of Cardiovascular Surgery, Xijing Hospital, Air Force Medical University 710032 China.

Jianguo Jia (J)

Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital Fudan University, Shanghai, China710032.
National Clinical Research Center for Interventional Medicine, Shanghai 200032, China.

Sanli Qian (S)

Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital Fudan University, Shanghai, China710032.
National Clinical Research Center for Interventional Medicine, Shanghai 200032, China.

Haichang Wang (H)

Xi'an International Medical Center Hospital Affiliated to Northwest University, Xi'an 710077, China.

Yang Yang (Y)

Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education, School of Life Sciences and Medicine, Northwest University, Xi'an, China.
Xi'an Key Laboratory of Cardiovascular and Cerebrovascular Diseases, Xi'an No.3 Hospital, The Affiliated Hospital of Northwest University, School of Life Sciences and Medicine, Northwest University, Xi'an, China.

Xin Wang (X)

Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.

Xiaoping Fan (X)

Department of Cardiovascular Surgery, Guangdong Provincial Hospital of Chinese Medicine, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, Guangdong, China.
The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong, China.

Jun Ren (J)

Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital Fudan University, Shanghai, China710032.
National Clinical Research Center for Interventional Medicine, Shanghai 200032, China.

Classifications MeSH